Abstract
Platelet activation and subsequent aggregation are implicated in most cardiovascular events. The oral agent, clopidogrel, is an irreversible inhibitor of the ADP-mediated pathway of platelet activation. It is licensed for secondary prevention of atherothrombotic events in patients suffering from myocardial infarction and acute coronary syndromes, but is also used for a number of off-label indications in particular, the prevention of stent thrombosis following percutaneous coronary intervention. The evidence base to support its use alone or in combination with aspirin therapy for these indications is presented here, alongside some of the key issues and problems related to clopidogrel use in clinical practice, with a specific focus on when treatment should be started, the use of loading doses and the optimal durations of therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
